IRLAB and McQuade Center for Strategic Research and Development (MSRD) Collaborate to Develop IRL757 for Apathy
Shots:
- IRLAB and MSRD (member of Otsuka Pharmaceutical) have collaborated to develop the former’s IRL757 for apathy through clinical PoC by incl. safety & efficacy studies in Parkinson's & Alzheimer's disease. IRL757’s P-I study recruitment is expected in Q2’24
- Under the agreement, IRLAB will obtain $3M up front & additional $5.5M on achieving certain development milestones. MSRD will cover the cost of drug development activities excl. P-I trial (funded by The Michael J. Fox Foundation)
- Furthermore, MSRD can choose to expand the partnership based on specific triggering events, pending negotiation of a new agreement. If collaboration doesn't expand, MSRD may receive low single-digit royalties under certain conditions
Ref: IRLAB Therapeutics | Image:IRLAB Therapeutics
Related News:- Ipsen Signs an Exclusive WW License Agreement with IRLAB for Mesdopetam to Treat Parkinson Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
